The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Eli Lilly’s trial testing its obesity pill found that the highest dose of the drug lowered participants weight by 10.5% ...

Shares of Chugai Pharmaceutical (OTCPK:CHGCY) closed ~6% higher on Wednesday after Eli Lilly (NYSE:LLY) announced that its ...

Reflecting this potential, Goldman Sachs analyst Asad Haider on August 15 reiterated a Buy rating on Eli Lilly and Company ...

A new release of Phase III data in diabetic patients related to Eli Lilly’s orforglipron signals a positive turnaround for ...

Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Elli Lily said on Tuesday that its daily weight loss pill helped patients lose weight, specifically those with obesity and ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

Eli Lilly (LLY) stock is up as the firm's oral weight loss drug orforglipron hits key goals in another Phase 3 trial, ...

The S&P 500 added 0.4% on Tuesday, Aug. 26, 2025, as investors looked past concerns about President Trump's move to fire a ...